Lung cancer Early Molecular Assessment

This study aimed to validate the potential utility of a clinically accessible, highly sensitive tumor-informed circulating tumor DNA (ctDNA) assay. The study considers a ‘landmark’ time period (between two weeks and four months after definitive treatment), as well as longitudinal sampling (>2 weeks) and compares two independent, retrospectively collected real-world cohorts.

Type: Exome Sequencing
Archiver: European Genome-Phenome Archive (EGA)

1 Dataset 1 Publication

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000001311	This dataset contains WES bam/bai files associated with 133 patients as part of the LEMA Study	Illumina NovaSeq 6000	133

Publications	Citations
Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation study. Schuurbiers MMF, Smith CG, Hartemink KJ, Rintoul RC, Gale D, Monkhorst K, Mandos BLR, Paterson AL, van den Broek D, Rosenfeld N, van den Heuvel MM, LEMA Study Group and the LUCID Study Group. PLoS Med 22: 2025 e1004574	3